Search details
1.
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults.
N Engl J Med
; 384(12): 1089-1100, 2021 03 25.
Article
in English
| MEDLINE | ID: mdl-33761206
2.
Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk.
PLoS Pathog
; 17(3): e1009363, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33720973
3.
Analysis of the HIV Vaccine Trials Network 702 Phase 2b-3 HIV-1 Vaccine Trial in South Africa Assessing RV144 Antibody and T-Cell Correlates of HIV-1 Acquisition Risk.
J Infect Dis
; 226(2): 246-257, 2022 08 24.
Article
in English
| MEDLINE | ID: mdl-35758878
4.
Longitudinal Dynamics of a Blood Transcriptomic Signature of Tuberculosis.
Am J Respir Crit Care Med
; 204(12): 1463-1472, 2021 12 15.
Article
in English
| MEDLINE | ID: mdl-34520313
5.
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
Clin Infect Dis
; 72(1): 50-60, 2021 01 23.
Article
in English
| MEDLINE | ID: mdl-31900486
6.
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
PLoS Med
; 17(5): e1003117, 2020 05.
Article
in English
| MEDLINE | ID: mdl-32442195
7.
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines.
PLoS Med
; 17(2): e1003038, 2020 02.
Article
in English
| MEDLINE | ID: mdl-32092060
8.
Assessment of the Safety and Immunogenicity of 2 Novel Vaccine Platforms for HIV-1 Prevention: A Randomized Trial.
Ann Intern Med
; 164(5): 313-22, 2016 Mar 01.
Article
in English
| MEDLINE | ID: mdl-26833336
9.
Factors associated with reactogenicity to an investigational HIV vaccine regimen in HIV vaccine trials network 702.
Vaccine
; 2024 May 21.
Article
in English
| MEDLINE | ID: mdl-38772835
10.
A novel HIV treatment model using private practitioners in South Africa.
Sex Transm Infect
; 88(2): 136-40, 2012 Mar.
Article
in English
| MEDLINE | ID: mdl-22345028
11.
Validation of a host blood transcriptomic biomarker for pulmonary tuberculosis in people living with HIV: a prospective diagnostic and prognostic accuracy study.
Lancet Glob Health
; 9(6): e841-e853, 2021 06.
Article
in English
| MEDLINE | ID: mdl-33862012
12.
Biomarker-guided tuberculosis preventive therapy (CORTIS): a randomised controlled trial.
Lancet Infect Dis
; 21(3): 354-365, 2021 03.
Article
in English
| MEDLINE | ID: mdl-33508224
13.
Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans.
PLoS One
; 15(1): e0226803, 2020.
Article
in English
| MEDLINE | ID: mdl-31999736
14.
Immune correlates of the Thai RV144 HIV vaccine regimen in South Africa.
Sci Transl Med
; 11(510)2019 09 18.
Article
in English
| MEDLINE | ID: mdl-31534016
15.
Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program.
Clin Infect Dis
; 47(11): 1479-85, 2008 Dec 01.
Article
in English
| MEDLINE | ID: mdl-18937580
16.
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial.
Lancet HIV
; 5(7): e366-e378, 2018 07.
Article
in English
| MEDLINE | ID: mdl-29898870
17.
Evaluation of a workplace HIV treatment programme in South Africa.
AIDS
; 21 Suppl 3: S73-8, 2007 Jul.
Article
in English
| MEDLINE | ID: mdl-17666964
18.
Continued Follow-Up of Phambili Phase 2b Randomized HIV-1 Vaccine Trial Participants Supports Increased HIV-1 Acquisition among Vaccinated Men.
PLoS One
; 10(9): e0137666, 2015.
Article
in English
| MEDLINE | ID: mdl-26368824
19.
Uptake of genital mucosal sampling in HVTN 097, a phase 1b HIV vaccine trial in South Africa.
PLoS One
; 9(11): e112303, 2014.
Article
in English
| MEDLINE | ID: mdl-25401780
20.
Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study.
Lancet Infect Dis
; 14(5): 388-96, 2014 May.
Article
in English
| MEDLINE | ID: mdl-24560541